Chronic Lymphocytic Leukemia News
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
Investigators compare efficacy and safety of obinutuzumab/chlorambucil, rituximab/ chlorambucil, and rituximab/bendamustine as frontline CLL treatments.
For patients with r/r CLL, acalabrutinib significantly improved progression-free survival compared with idelalisib-rituximab or bendamustine-rituximab.
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Patients with previously untreated CLL with comorbidities continued to experience greater benefits with venetoclax-obinutuzumab compared with chlorambucil-obinutuzumab.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
In this study, the incidence of laboratory tumor lysis syndrome was 13% in a cohort of patients with relapsed CLL treated with venetoclax in a “real world” setting.
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
CAR-T therapy combined with concurrent ibrutinib is well tolerated in patients with relapsed or refractory CLL.
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.